Medical treatment and radiotherapy are the main methods of conservative treatment of renal cancer

Surgery is currently the main way to treat kidney cancer in clinical practice, but some patients do not meet the surgical indications or are physically intolerant of surgery, so conservative treatment is required. Conservative treatment of kidney cancer mainly includes medical treatment and radiotherapy.

Medical treatment

Currently, IFN-α or (and) IL-2 is the first-line treatment for metastatic renal cell carcinoma, and its treatment efficiency is about 15%. The results of randomized controlled clinical studies have not yet proved that LAK cells, TIL cells, and IFN-γ are effective in treating metastatic renal cell carcinoma. The efficacy of commonly used chemotherapy drugs (whether used alone or in combination) for metastatic renal cell carcinoma has not yet been determined, and chemotherapy combined with IFN-α or (and) IL-2 has not shown an advantage. In recent years, chemotherapy based on difluorodeoxycytidine has achieved certain efficacy in metastatic renal cell carcinoma and can also be used as a first-line treatment.

The new drug "Sorafenib" is a multi-target kinase inhibitor targeting the vascular endothelial growth factor receptor. It has an efficacy of 10% to 40% in treating metastatic renal cancer and is a relatively promising drug for the clinical treatment of renal cancer.

Radiation therapy

Palliative radiotherapy can relieve pain and improve the quality of life for patients with local tumor bed recurrence, regional or distant lymph node metastasis, bone or lung metastasis. Stereotactic radiotherapy, three-dimensional conformal radiotherapy and intensity-modulated conformal radiotherapy developed in recent years can play a better role in controlling recurrent or metastatic lesions.